Teva Pharmaceutical Industries Limited
TEVA
$18.46
-$0.34-1.81%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.29% | 1.89% | -5.12% | 12.52% | 7.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.29% | 1.89% | -5.12% | 12.52% | 7.37% |
| Cost of Revenue | -3.08% | -1.66% | 3.33% | 9.20% | 2.79% |
| Gross Profit | 3.85% | 5.99% | -12.25% | 16.10% | 12.69% |
| SG&A Expenses | 2.13% | 3.72% | 5.54% | 9.48% | 3.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 600.00% | 111.76% | -22.22% | -171.43% | 95.83% |
| Total Operating Expenses | -1.94% | 0.73% | 4.05% | 7.74% | 4.33% |
| Operating Income | 9.42% | 7.42% | -28.62% | 31.93% | 21.94% |
| Income Before Tax | 183.27% | 162.42% | -148.62% | -593.85% | 73.46% |
| Income Tax Expenses | -112.38% | 242.31% | -31.71% | 675.00% | 4,037.50% |
| Earnings from Continuing Operations | 132.23% | 152.51% | -158.89% | -606.49% | 3.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -102.14% | 1,550.00% | -487.50% | -17.14% |
| Net Income | 133.33% | 253.96% | -146.87% | -733.33% | 2.98% |
| EBIT | 9.42% | 7.42% | -28.62% | 31.93% | 21.94% |
| EBITDA | 6.41% | 2.25% | -23.40% | 20.98% | 10.93% |
| EPS Basic | 132.93% | 251.86% | -146.37% | -726.14% | 4.10% |
| Normalized Basic EPS | 1.74% | -45.42% | -23.78% | 38.81% | 35.06% |
| EPS Diluted | 132.00% | 245.40% | -147.46% | -750.00% | 3.85% |
| Normalized Diluted EPS | 0.49% | -46.41% | -22.69% | 40.54% | 35.06% |
| Average Basic Shares Outstanding | 1.24% | 1.34% | 1.07% | 1.07% | 1.16% |
| Average Diluted Shares Outstanding | 2.47% | 3.21% | -0.35% | -0.18% | 1.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |